KR20230019937A - 암 요법에서 표적화할 수 없는 kras의 표적화된 분해를 위한 신규한 소분자 - Google Patents

암 요법에서 표적화할 수 없는 kras의 표적화된 분해를 위한 신규한 소분자 Download PDF

Info

Publication number
KR20230019937A
KR20230019937A KR1020237000112A KR20237000112A KR20230019937A KR 20230019937 A KR20230019937 A KR 20230019937A KR 1020237000112 A KR1020237000112 A KR 1020237000112A KR 20237000112 A KR20237000112 A KR 20237000112A KR 20230019937 A KR20230019937 A KR 20230019937A
Authority
KR
South Korea
Prior art keywords
compound
kras
group
cancer
carbonyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
KR1020237000112A
Other languages
English (en)
Korean (ko)
Inventor
닥터 바스카란 필라이
디네쉬 엠.지.
Original Assignee
필라이 유니버셜 엘엘씨
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 필라이 유니버셜 엘엘씨 filed Critical 필라이 유니버셜 엘엘씨
Publication of KR20230019937A publication Critical patent/KR20230019937A/ko
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/81—Amides; Imides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
KR1020237000112A 2020-06-04 2021-05-26 암 요법에서 표적화할 수 없는 kras의 표적화된 분해를 위한 신규한 소분자 Pending KR20230019937A (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
IN202041023434 2020-06-04
IN202041023434 2020-06-04
PCT/IB2021/054591 WO2021245499A1 (en) 2020-06-04 2021-05-26 Novel small molecules for targeted degradation of untargetable kras in cancer therapy

Publications (1)

Publication Number Publication Date
KR20230019937A true KR20230019937A (ko) 2023-02-09

Family

ID=78830675

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020237000112A Pending KR20230019937A (ko) 2020-06-04 2021-05-26 암 요법에서 표적화할 수 없는 kras의 표적화된 분해를 위한 신규한 소분자

Country Status (11)

Country Link
US (1) US20230202981A1 (https=)
EP (1) EP4161511B1 (https=)
JP (1) JP7789016B2 (https=)
KR (1) KR20230019937A (https=)
CN (2) CN115768427B (https=)
AU (1) AU2021284517A1 (https=)
BR (1) BR112022024300A2 (https=)
CA (1) CA3180686A1 (https=)
IL (1) IL298672A (https=)
MX (1) MX2022015253A (https=)
WO (1) WO2021245499A1 (https=)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019217307A1 (en) 2018-05-07 2019-11-14 Mirati Therapeutics, Inc. Kras g12c inhibitors
EA202190749A1 (ru) 2018-09-10 2021-07-09 Мирати Терапьютикс, Инк. Способы комбинированной терапии
EP3849535A4 (en) 2018-09-10 2022-06-29 Mirati Therapeutics, Inc. Combination therapies
JP2022500385A (ja) 2018-09-10 2022-01-04 ミラティ セラピューティクス， インコーポレイテッド 組み合わせ療法
EP3849537B1 (en) 2018-09-10 2024-10-23 Mirati Therapeutics, Inc. Combination therapies
MX2021002804A (es) 2018-12-05 2021-07-15 Mirati Therapeutics Inc Terapias de combinacion.
EP3908283A4 (en) 2019-01-10 2022-10-12 Mirati Therapeutics, Inc. KRAS G12C INHIBITORS
MX2022002465A (es) 2019-08-29 2022-05-19 Mirati Therapeutics Inc Inhibidores de kras g12d.
WO2021061749A1 (en) 2019-09-24 2021-04-01 Mirati Therapeutics, Inc. Combination therapies
PH12022551513A1 (en) 2019-12-20 2023-04-24 Mirati Therapeutics Inc Sos1 inhibitors
EP4210833A4 (en) 2020-09-11 2024-09-11 Mirati Therapeutics, Inc. CRYSTALLINE FORMS OF A KRAS G12C INHIBITOR
JP2023553492A (ja) 2020-12-15 2023-12-21 ミラティ セラピューティクス， インコーポレイテッド アザキナゾリン汎ＫＲａｓ阻害剤
EP4262803A4 (en) 2020-12-16 2025-03-12 Mirati Therapeutics, Inc. Tetrahydropyridopyrimidine pan-kras inhibitors
WO2025083563A1 (en) * 2023-10-18 2025-04-24 Pillai Universal Llc Effective therapeutic small-molecule inhibitors for metastatic cancer
WO2025083561A1 (en) * 2023-10-18 2025-04-24 Pillai Universal Llc Novel lead small molecule inhibitors on undruggable target towards anticancer activity
WO2025083564A1 (en) * 2023-10-18 2025-04-24 Pillai Universal Llc Novel small molecule degrader as a potential anticancer
WO2025083568A1 (en) * 2023-10-18 2025-04-24 Pillai Universal Llc Novel small-molecule protein kinase inhibitors for implications in cancer treatment
WO2025083570A1 (en) * 2023-10-18 2025-04-24 Pillai Universal Llc Novel small-molecule agents in overcoming tumor regression in cancers

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
OA12274A (en) * 2000-05-22 2006-05-09 Aventis Pharma Inc Arylmethylamine derivatives for use as tryptase inhibitors.
GB0012362D0 (en) * 2000-05-22 2000-07-12 Aventis Pharma Ltd Chemical compounds
HUP0402106A3 (en) * 2001-11-01 2009-07-28 Janssen Pharmaceutica Nv Heteroaryl amines as glycogen synthase kinase 3 beta inhibitors, process for their preparation and pharmaceutical compositions containing them
WO2007075896A2 (en) * 2005-12-22 2007-07-05 Kemia, Inc. Heterocyclic cytokine inhibitors
JP2013525308A (ja) * 2010-04-16 2013-06-20 キュリス，インコーポレイテッド Ｋ−ｒａｓ変異を有する癌の治療
US20190284149A1 (en) * 2014-09-12 2019-09-19 Ariagen, Inc. Aryl hydrocarbon receptor modulator
CN106317055A (zh) * 2015-07-02 2017-01-11 中国科学院上海药物研究所 一类具有激酶抑制活性的化合物、制备方法和用途
WO2018140513A1 (en) * 2017-01-26 2018-08-02 Araxes Pharma Llc 1-(3-(6-(3-hydroxynaphthalen-1-yl)benzofuran-2-yl)azetidin-1yl)prop-2-en-1-one derivatives and similar compounds as kras g12c modulators for treating cancer
CN110885332B (zh) * 2019-12-06 2022-03-18 中国人民解放军第二军医大学 一种PDEδ蛋白降解靶向嵌合体及其制备方法和应用

Also Published As

Publication number Publication date
EP4161511A1 (en) 2023-04-12
JP7789016B2 (ja) 2025-12-19
MX2022015253A (es) 2023-03-14
IL298672A (en) 2023-01-01
BR112022024300A2 (pt) 2023-01-24
TW202210465A (zh) 2022-03-16
CN115768427B (zh) 2025-03-28
WO2021245499A1 (en) 2021-12-09
CN115768427A (zh) 2023-03-07
EP4161511B1 (en) 2026-04-29
AU2021284517A1 (en) 2023-01-05
JP2023529354A (ja) 2023-07-10
EP4161511A4 (en) 2024-07-17
CN120208921A (zh) 2025-06-27
US20230202981A1 (en) 2023-06-29
CA3180686A1 (en) 2021-12-09

Similar Documents

Publication Publication Date Title
JP7789016B2 (ja) 癌治療における標的化不能ｋｒａの標的分解のための新規の小分子
US20240082218A1 (en) Pharmaceutical combinations comprising a kras g12c inhibitor and uses of a kras g12c inhibitor for the treatment of cancers
EP3585389A1 (en) Treatment of egfr-driven cancer with fewer side effects
KR20140096375A (ko) 항종양제의 효과 증강제
CN107666906A (zh) 用于治疗癌症的方法
WO2014002922A1 (ja) 抗癌剤の併用による癌治療方法
JP6373252B2 (ja) オーロラキナーゼ阻害薬を使用する癌の治療方法
Dienstmann et al. Recent developments in anti-cancer agents targeting PI3K, Akt and mTORC1/2
US20080214521A1 (en) Sensitization of Drug-Resistant Lung Caners to Protein Kinase Inhibitors
TWI916370B (zh) 用於在癌症治療中對不可標定之kras進行降解標定之新穎小分子
RU2839932C1 (ru) Новые малые молекулы для целенаправленного расщепления не поддающегося целенаправленному воздействию kras в терапии рака
WO2024137751A1 (en) Methods of treating advanced solid tumors
WO2020254299A1 (en) Combination of a mcl-1 inhibitor and a standard of care treatment for breast cancer, uses and pharmaceutical compositions thereof
AU2016296997A1 (en) Chlorobenzene substituted azaaryl compounds
WO2015153866A1 (en) Cancer therapy with ganetespib and an egfr inhibitor
Greco Synthesis and biological evaluation of pyrazolo [3, 4-d] pyrimidine derivatives active as SGK1, Fyn and Src kinases inhibitors
US20180303797A1 (en) Chalcone Compounds
US12036215B2 (en) Antitumor agent and method for tumor therapy
GB2643430A (en) Nuclear transport inhibitors for anti-cancer combination therapy
TW201605449A (zh) 馬賽替尼治療結腸直腸癌的用途
JP2015163592A (ja) 抗癌剤の併用による癌治療方法
Neuwelt et al. Silmitasertib. Casein kinase 2 (CK2) inhibitor, Treatment of solid and hematologic malignancies
JP2015163591A (ja) 抗癌剤の併用による癌治療方法
JP2014091712A (ja) Ｈｓｐ９０阻害剤と抗腫瘍性タキサン化合物との組み合わせ
HK1233924A1 (en) Derivatives of cephalosporin for treating cancer

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20230102

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
A201 Request for examination
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20240521

Comment text: Request for Examination of Application